These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 37059343)

  • 1. In vitro activity of imipenem/relebactam, meropenem/vaborbactam and comparators against Enterobacterales causing urinary tract infection in Taiwan: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2020.
    Chang CY; Lee YL; Huang YT; Ko WC; Ho MW; Hsueh PR
    Int J Antimicrob Agents; 2023 Jun; 61(6):106815. PubMed ID: 37059343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
    Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals.
    Castanheira M; Doyle TB; Deshpande LM; Mendes RE; Sader HS
    Int J Antimicrob Agents; 2021 Nov; 58(5):106439. PubMed ID: 34547421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-susceptibilities to antibiotics against important Gram-negative bacteria, and imipenem-relebactam, meropenem-vaborbactam against carbapenem non-susceptible Enterobacterales and Pseudomonas aeruginosa isolates implicated in complicated intra-abdominal and urinary tract infections in Taiwan, 2019.
    Jean SS; Lu MC; Ho MW; Ko WC; Hsueh PR;
    Int J Antimicrob Agents; 2022 Mar; 59(3):106521. PubMed ID: 35066144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial activity of ceftazidime-avibactam against KPC-2-producing Enterobacterales: a cross-combination and dose-escalation titration study with relebactam and vaborbactam.
    Kang MS; Baek JY; Ko J-H; Cho SY; Lee KY; Lee YH; Yang J; Kim TY; Huh HJ; Lee NY; Huh K; Kang C-I; Chung DR; Peck KR
    Microbiol Spectr; 2024 Jun; 12(6):e0034424. PubMed ID: 38687076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Susceptibility evaluation of novel beta-lactam/beta-lactamase inhibitor combinations against carbapenem-resistant Klebsiella pneumoniae from bloodstream infections in hospitalized patients in Brazil.
    Wilhelm CM; Antochevis LC; Magagnin CM; Arns B; Vieceli T; Pereira DC; Lutz L; de Souza ÂC; Dos Santos JN; Guerra RR; Medeiros GS; Santoro L; Falci DR; Rigatto MH; Barth AL; Martins AF; Zavascki AP
    J Glob Antimicrob Resist; 2024 Sep; 38():247-251. PubMed ID: 38936472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of novel β-lactam/β-lactamase inhibitor combinations against serine carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa.
    Lee SY; Gill CM; Nicolau DP;
    J Antimicrob Chemother; 2023 Dec; 78(12):2795-2800. PubMed ID: 37840005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenotypes, genotypes and breakpoints: an assessment of β-lactam/β-lactamase inhibitor combinations against OXA-48.
    Asempa TE; Kois AK; Gill CM; Nicolau DP
    J Antimicrob Chemother; 2023 Mar; 78(3):636-645. PubMed ID: 36626311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenotypes, genotypes and breakpoints: an assessment of β-lactam/ β-lactamase inhibitor combinations against OXA-48.
    Asempa TE; Kois AK; Gill CM; Nicolau DP
    J Antimicrob Chemother; 2022 Sep; 77(10):2622-2631. PubMed ID: 35325165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of aztreonam-avibactam against Enterobacterales resistant to recently approved beta-lactamase inhibitor combinations collected in Europe, Latin America, and the Asia-Pacific Region (2020-2022).
    Sader HS; Carvalhaes CG; Kimbrough JH; Mendes RE; Castanheira M
    Int J Antimicrob Agents; 2024 Apr; 63(4):107113. PubMed ID: 38354826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Susceptibility of OXA-48-producing Enterobacterales to imipenem/relebactam, meropenem/vaborbactam and ceftazidime/avibactam.
    Bonnin RA; Bernabeu S; Emeraud C; Creton E; Vanparis O; Naas T; Jousset AB; Dortet L
    Int J Antimicrob Agents; 2022 Oct; 60(4):106660. PubMed ID: 35988666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of Imipenem-Relebactam and Meropenem-Vaborbactam against Carbapenem-Resistant, SME-Producing Serratia marcescens.
    Biagi M; Shajee A; Vialichka A; Jurkovic M; Tan X; Wenzler E
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31932381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiology and antimicrobial susceptibility profiles of Enterobacterales causing bloodstream infections before and during COVID-19 pandemic: Results of the Study for Monitoring Antimicrobial Resistance Trends (SMART) in Taiwan, 2018-2021.
    Lee YL; Liu CE; Tang HJ; Huang YT; Chen YS; Hsueh PR;
    J Microbiol Immunol Infect; 2024 Jun; 57(3):446-456. PubMed ID: 38632023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Minor Carbapenemases on Susceptibility to Novel β-Lactam/β-Lactamase Inhibitor Combinations and Cefiderocol in
    Sadek M; Bosch Duran J; Poirel L; Nordmann P
    Antimicrob Agents Chemother; 2023 May; 67(5):e0007823. PubMed ID: 37039645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multidrug-resistant Gram-negative clinical isolates with reduced susceptibility/resistance to cefiderocol: which are the best present and future therapeutic alternatives?
    Le Terrier C; Freire S; Nordmann P; Poirel L
    Eur J Clin Microbiol Infect Dis; 2024 Feb; 43(2):339-354. PubMed ID: 38095831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Vitro Activity of Imipenem-Relebactam, Meropenem-Vaborbactam, Ceftazidime-Avibactam and Comparators on Carbapenem-Resistant Non-Carbapenemase-Producing Enterobacterales.
    Bonnin RA; Bernabeu S; Emeraud C; Naas T; Girlich D; Jousset AB; Dortet L
    Antibiotics (Basel); 2023 Jan; 12(1):. PubMed ID: 36671303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meropenem-Vaborbactam Activity against U.S. Multidrug-Resistant
    Shortridge D; Kantro V; Castanheira M
    Microbiol Spectr; 2023 Feb; 11(1):e0450722. PubMed ID: 36622238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imipenem-Relebactam Susceptibility in
    Hernández-García M; García-Castillo M; Bou G; Cercenado E; Delgado-Valverde M; Oliver A; Pitart C; Rodríguez-Lozano J; Tormo N; Melo-Cristino J; Pinto MF; Gonçalves E; Alves V; Vieira AR; Ramalheira E; Sancho L; Diogo J; Ferreira R; Cruz H; Chaves C; Duarte J; Pássaro L; Díaz-Regañón J; Cantón R
    Microbiol Spectr; 2022 Oct; 10(5):e0292722. PubMed ID: 36043877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam activities against multidrug-resistant Enterobacterales from United States Medical Centers (2018-2022).
    Sader HS; Mendes RE; Duncan L; Kimbrough JH; Carvalhaes CG; Castanheira M
    Diagn Microbiol Infect Dis; 2023 Jun; 106(2):115945. PubMed ID: 37060707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Activities of Novel Therapeutic Agents against Molecularly Characterized Clinical Carbapenem-Resistant
    Teo JQ; Chang HY; Tan SH; Tang CY; Ong RT; Ko KKK; Chung SJ; Tan TT; Kwa AL
    Microbiol Spectr; 2023 Jun; 11(3):e0100223. PubMed ID: 37184408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.